Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks, et al.
Drugs (2021) Vol. 81, Iss. 14, pp. 1605-1626
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Multiple Sclerosis: Inflammatory and Neuroglial Aspects
Giulio Papiri, Giordano D’Andreamatteo, Gabriella Cacchiò, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 2, pp. 1443-1470
Open Access | Times Cited: 48
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
Ewa Robak, Tadeusz Robak
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2807-2807
Open Access | Times Cited: 47
Fighting Post-COVID and ME/CFS – development of curative therapies
Carmen Scheibenbogen, Judith Bellmann‐Strobl, Cornelia Heindrich, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 35
Future landscape for the management of membranous nephropathy
Fernando Caravaca‐Fontán, Federico Yandián, Fernando C. Fervenza
Clinical Kidney Journal (2023) Vol. 16, Iss. 8, pp. 1228-1238
Open Access | Times Cited: 24
Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
Stefanie Fischer, Undine Proschmann, Katja Akgün, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3177-3177
Open Access | Times Cited: 33
Aberrant B Cell Signaling in Autoimmune Diseases
Odilia B. J. Corneth, Stefan F. H. Neys, Rudi W. Hendriks
Cells (2022) Vol. 11, Iss. 21, pp. 3391-3391
Open Access | Times Cited: 26
Systematic simulation of the interactions of pleckstrin homology domains with membranes
Kyle I. P. Le Huray, He Wang, Frank Sobott, et al.
Science Advances (2022) Vol. 8, Iss. 27
Open Access | Times Cited: 23
Nanoparticle-neutrophils interactions for autoimmune regulation
Daniel Kupor, Michael L. Felder, Shivanie Kodikalla, et al.
Advanced Drug Delivery Reviews (2024) Vol. 209, pp. 115316-115316
Open Access | Times Cited: 6
Aberrant B cell receptor signaling in circulating naïve and IgA+ memory B cells from newly-diagnosed autoantibody-positive rheumatoid arthritis patients
Stefan F. H. Neys, Judith W Heutz, Jennifer A. C. van Hulst, et al.
Journal of Autoimmunity (2024) Vol. 143, pp. 103168-103168
Open Access | Times Cited: 5
Neutrophils in autoimmunity: when the hero becomes the villain
Samal Bissenova, Darcy Ellis, Chantal Mathieu, et al.
Clinical & Experimental Immunology (2022) Vol. 210, Iss. 2, pp. 128-140
Open Access | Times Cited: 21
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline
Chi Chiu Mok
Drugs (2023) Vol. 83, Iss. 6, pp. 479-496
Open Access | Times Cited: 12
Pharmacology of drugs used in autoimmune dermatopathies in cats and dogs: A narrative review
Heng L. Tham, Jennifer L. Davis
Veterinary Dermatology (2024) Vol. 35, Iss. 4, pp. 453-476
Open Access | Times Cited: 4
Rituximab in chronic immune mediated neuropathies: a systematic review
Sai S. Chaganti, Andrew Hannaford, Steve Vucic
Neuromuscular Disorders (2022) Vol. 32, Iss. 8, pp. 621-627
Closed Access | Times Cited: 19
Bruton's Tyrosine Kinase – A New Target for Immune Mediated Inflammatory Diseases?
John D. Isaacs
Seminars in Arthritis and Rheumatism (2025), pp. 152681-152681
Open Access
Design, Synthesis, and Biological Evaluation of Pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Potent and Orally Available Noncovalent Bruton’s Tyrosine Kinase (BTK) Inhibitors
Chaoquan Tian, Hongguang Du, Wenjie Sha, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
Nicolas Collongues, Guillaume Becker, Valérie Jolivel, et al.
Neurology and Therapy (2022) Vol. 11, Iss. 3, pp. 981-1042
Open Access | Times Cited: 13
Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
Edgar Carnero Contentti, Jorge Correale
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3473-3490
Open Access | Times Cited: 13
The Autoimmune Manifestations in Patients with Genetic Defects in the B Cell Development and Differentiation Stages
Gholamreza Azizi, Mina Fattah Hesari, Niusha Sharifinejad, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 4, pp. 819-834
Open Access | Times Cited: 7
PGRN Inhibits Early B‐cell Activation and IgE Production Through the IFITM3‐STAT1 Signaling Pathway in Asthma
Pingping Zhang, Changshun Ruan, Guangli Yang, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study
Philip G. Conaghan, Miroslawa Nowak, Shuyan Du, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 5, pp. e263-e273
Open Access | Times Cited: 6
Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation
Wenqi Li, Shuwen Zhu, Jing Liu, et al.
Molecules (2023) Vol. 28, Iss. 16, pp. 6035-6035
Open Access | Times Cited: 6
Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase
Kaixuan Li, Mingqian Wang, Melike Akoglu, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 3, pp. 410-421
Open Access | Times Cited: 5
Virtual screening and structure–activity relationship study of novel BTK inhibitors in Traditional Chinese Medicine for the treatment of rheumatoid arthritis
Lili Sun, Zixiao Wang, Zhigang Yang, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 24, pp. 15219-15233
Closed Access | Times Cited: 5
Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis
Barbara Nuesslein‐Hildesheim, Enrico Ferrero, Cindy Schmid, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 5
Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities
Ana Neves, Luísa Viveiros, Veronica Venturelli, et al.
Research and Reports in Urology (2023) Vol. Volume 15, pp. 333-353
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top